Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q2 2023 call → NOThe question asks whether management explains the company's business direction by narrating what its counterparties are themselves doing and scaling. Let me analyze the transcript carefully. Key counterparties mentioned: 1. Kedrion - distribution partner for KEDRAB in the U.S. 2. CSL Behring - manufacturer of CYTOGAM (but this is a supply relationship, not a growth driver) 3. FIMI - investor, not a counterparty in the operational sense Let me examine how Kedrion is discussed: - "Kedrion has exercised its option to extend our distribution agreement for KEDRAB in the U.S. through March 2026" - "we remain in active discussion with Kedrion to potentially further expand the scope of our collaboration" - "During 2022, we generated approximately $16 million in revenue from sales of KEDRAB to Kedrion for further distribution in the U.S. market" - "During the first six months of this year, we experienced a significant increase in demand for the product in the U.S., and we anticipate even further momentum in the second half of the year" Now, does management narrate Kedrion's own trajectory as the driver of Kamada's growth? Let me look at the KEDRAB discussion more carefully: Amir says: "we were pleased to announce last month that Kedrion has exercised its option to extend our distribution agreement for KEDRAB in the U.S. through March 2026. Moreover, we remain in active discussion with Kedrion to potentially further expand the scope of our collaboration." Then: "During the first six months of this year, we experienced a significant increase in demand for the product in the U.S., and we anticipate even further momentum in the second half of the year that includes the summer months." And in the Q&A about KEDRAB market dynamics: "we do experience a significant increase in demand, a significant increase in our supply to Kedrion for further sales in the U.S. market. We expect that those dynamics and that trend to continue moving forward for the rest of this year and into 2024, 2025. So we are taking significant market share in this $150 million market." Then he describes: "we are very happy with the strong collaboration with the Kedrion team in the southern marketing of the product-induced market. We believe and we actually see that the teams are doing very well.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.